Phaseline

Targets › NR2E3

NR2E3 (Photoreceptor-specific nuclear receptor): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Ophthalmology; next expected readout Feb 2027.

Orphan nuclear receptor of retinal photoreceptor cells. Transcriptional factor that is an activator of rod development and repressor of cone development. (UniProt, Q9Y5X4)

Open in Phaseline: the race on NR2E3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OcugenOCU400
Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis
RHO, NR2E3, CEP290Phase 3Retinitis PigmentosaFeb 2027

Conditions

Retinitis Pigmentosa (2)

Modalities

other (1)

Companies

Ocugen (1)

Related targets

RHO (1) CEP290 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.